AI Terminal
Intrasense
Earnings Release • Dec 18, 2025
1447_iss_2025-12-18_55ac5ce8-6887-4ab3-bba2-3c6f203b271a.pdf
Earnings Release
Open in ViewerOpens in native device viewer
Intrasense confirms its 2025 financial targets and updates its strategic roadmap
Montpellier, December 18, 2025. Intrasense (ISIN: FR0011179886), French expert in medical imaging solutions to assist diagnosis, decision-making and therapeutic follow-up, confirms its financial targets for the 2025 fiscal year and updates the strategic roadmap presented in March 20251 .
PILLAR 1: Product innovation
Version 3.x of Liflow®, certified in August 2025, is currently being deployed at the two partner sites as part of the "Oncology Assistant" project funded by Bpifrance.
The CE marking of DUOnco™Bones and DUOnco™Pancreas in the second half of the year strengthens the depth and clinical value of Intrasense's oncology portfolio.
PILLAR 2: Expansion of product range
In order to ensure a controlled deployment of the new version of Liflow®, Intrasense has chosen to implement a Controlled Release phase, i.e. a launch limited to three pilot centers, to continue clinical and technical validation work under real-life conditions. This phase aims to consolidate field feedback during the first half of 2026, before considering a broader commercial rollout.
In parallel, DUOnco™ Bones and DUOnco™ Pancreas have generated encouraging initial commercial discussions.
PILLAR 3: Geographic expansion
Despite an initial pilot at the beginning of the year with Guerbet in Italy, the second half of the year did not demonstrate sufficient traction. As a result, Intrasense has adjusted its commercial approach and executed a pivot toward imaging Artificial Intelligence marketplaces to rapidly broaden market access.
PILLAR 4: Optimized resource management
In order to align its resources with the pace of business development, which has been slower than initially anticipated, Intrasense is implementing a cost-saving plan that includes a reduction in headcount and external expenses.
Its implementation will be gradual, starting in early 2026, with no impact on business continuity or ongoing commercial commitments.
These measures are fully aligned with the Company's path toward a return to financial breakeven.
1 Press release on March 26th 2025
2025 Financial targets confirmed
Intrasense teams remain fully mobilized around the Myrian® and DUOnco™ product ranges, enabling the Company to confirm its targets for the 2025 fiscal year, namely:
- 2025 revenue of around €3.0 million, representing growth of approximately 30%.
- Order intake exceeding €5.5 million, relating to multi-year license and maintenance contracts. As part of these orders has already been invoiced in 2025, the secured backlog for the 2026– 2029 period amounts to approximately €3.0 million.
The Company's cash position remains under pressure, and Intrasense is currently reviewing all available options to finance its growth.
About Intrasense
A French expert in medical imaging since 2004 and a digital subsidiary of the Guerbet Group, Intrasense designs medical imaging software solutions natively enriched by artificial intelligence algorithms.
Myrian®, an advanced radiology visualization platform featuring cutting-edge clinical tools, optimizes and simplifies the interpretation of all types of images. DUOnco™, a range of expert AI algorithms for oncology, offers an AI for the detection of focal liver lesions and the first AI dedicated to CE-marked bone lesions. Liflow®, a dedicated oncology monitoring solution integrating multi-organ AIs, optimizes the longitudinal monitoring of cancer patients.
By combining clinical expertise and operational performance, Intrasense provides healthcare professionals with high medical value tools, facilitating analysis, diagnosis and patient management.
More information on www.intrasense.fr
Contacts
INTRASENSE
Communication officer
Salomé Sylvestre Phone : +334 67 13 01 30 [email protected]
SEITOSEI.ACTIFIN
Analyst & Investor Relations
Foucauld Charavay Phone : +336 37 83 33 19 [email protected]
Press Relations
Isabelle Dray Phone.: +331 56 88 11 29 [email protected]
Press Release 2/2